

## Update on Submission of Final Module to FDA

**Sunnyvale, California; 15 November 2023:** EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, wishes to provide a status update regarding the Company’s Premarket Approval Application (“PMA”) to the U.S. Food and Drug Administration (“FDA”). EBR has submitted four out of five required modules for the PMA submission (as previously disclosed), and now expects to submit the final module in Q3 2024.

The updated timeline is a result of new information relating to the proposed testing schedule received from an expert consultant involved in the design verification testing required for the final module. The new testing schedule has been expanded by a short period, meaning the final module will not be able to be submitted in Q1 2024. However, EBR expects the new testing schedule to increase the strength of the Company’s PMA submission and place EBR in a better position to receive FDA approval without further delay. The Company will continue to benefit from the FDA Breakthrough Device Designation.

EBR’s clinical data remains unchanged with the pivotal study results meeting the primary safety and efficacy endpoints, while the costs of the planned expanded testing are minimal.

EBR is now targeting FDA approval during Q1 2025 and remains well funded through initial commercialisation.

### **John McCutcheon, EBR Systems’ President & Chief Executive Officer said:**

*“As part of our commitment to ensuring the highest quality of the WiSE CRT system, we have made the strategic decision to reforecast the timing of our final PMA module. We believe that the benefits from additional testing have the potential to demonstrate increased durability and longevity of the WiSE CRT device, resulting in a more robust PMA submission. Given we have already submitted four modules to date, we are confident in this updated timeline and remain well capitalised through to the initial commercialisation phase.”*

***This announcement has been authorised for release by General Disclosure Committee, a Committee of the Board.***

**For more information, please contact:**

#### **Company**

Gary Doherty  
Chief Financial Officer  
P: +1 408 720 1906  
E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

#### **Investors**

Dean Dribbin  
Vesparum Capital  
P: +61 3 8582 4800  
E: [EBRSystems@vesparum.com](mailto:EBRSystems@vesparum.com)

### **About EBR Systems (ASX: EBR)**

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

### **EBR Systems’ WiSE Technology**

EBR Systems’ WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle. This has long been a goal of cardiac pacing companies

since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

### **Foreign Ownership Restriction**

EBR's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.